Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Dinutuximab‐containing immunotherapy vs usual care

Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
HR 0.5 [0.31, 0.8]
1 study · 226 participants
Moderate

Retinoic acid post‐consolidation therapy vs no further treatment

Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT

Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
HR 0.87 [0.46, 1.63]
1 study · 98 participants
Low